We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In the first public disclosure of data on RXC006, Dr Peter Bunyard, Head of Fibrosis at Redx, presented results from preclinical studies in a plenary session as well as a poster which showed that RXC006 was highly effective at suppressing the Wnt pathway
In the first public disclosure of data on RXC006, Dr Peter Bunyard, Head of Fibrosis at Redx, presented results from preclinical studies in a plenary session as well as a poster which showed that RXC006 was highly effective at suppressing the Wnt pathway